相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
D. Ross Camidge et al.
ANTI-CANCER DRUGS (2009)
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
F. Morschhauser et al.
ANNALS OF ONCOLOGY (2008)
Protein kinase C-β inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis
Arkadiusz Z. Dudek et al.
INVESTIGATIONAL NEW DRUGS (2008)
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia
Xavier Leleu et al.
BLOOD (2007)
Inhibition of protein kinase cβ by enzastaurin enhances radiation cytotoxicity in pancreatic cancer
Aaron C. Spalding et al.
CLINICAL CANCER RESEARCH (2007)
The therapeutic role of targeting protein kinase C in solid and hematologic malignancies
Klaus Podar et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia
Anne-Sophie Moreau et al.
BLOOD (2007)
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
Michael J. Robertson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Heterogeneity of protein kinase C β2 expression in lymphoid malignancies
A-V Decouvelaere et al.
HISTOPATHOLOGY (2007)
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)
Klaus Podar et al.
BLOOD (2007)
Synergistic antiglioma activity of radiotherapy and enzastaurin
Ghazaleh Tabatabai et al.
ANNALS OF NEUROLOGY (2007)
B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CβII
Simon T. Abrams et al.
BLOOD (2007)
Protein kinase C β enhances growth and expression of cyclin D1 in human breast cancer cells
Haiyang Li et al.
CANCER RESEARCH (2006)
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer
Michael A. Carducci et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines
Mujahid A. Rizvi et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The selective protein kinase C β inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway
Christiane Querfeld et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors
LV Beerepoot et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
PKCβ regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1
H Shinohara et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma
CP Hans et al.
MODERN PATHOLOGY (2005)
The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts
JR Graff et al.
CANCER RESEARCH (2005)
The activation of Akt/PKB signaling pathway and cell survival
G Song et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2005)
LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice
KA Keyes et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma
AM Dring et al.
CLINICAL CANCER RESEARCH (2004)
Protein kinase C βII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion
Y Kawakami et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Acyclic N-(azacycloalkyl)bisindolylmaleimides:: Isozyme selective inhibitors of PKCβ
MM Faul et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Protein kinase C β controls nuclear factor κB activation in B cells through selective regulation of the IκB kinase α
K Saijo et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Characterization of protein kinase C β isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization
K Suzuma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Antiangiogenic effects of a protein kinase C beta-selective small molecule
BA Teicher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
MA Shipp et al.
NATURE MEDICINE (2002)
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
K Podar et al.
BLOOD (2001)
Alteration in the expression of protein kinase C isoforms in human hepatocellular carcinoma
JH Tsai et al.
CANCER LETTERS (2000)
Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms
A Balendran et al.
FEBS LETTERS (2000)
分享论文
